Table 1

Main outcomes of the BLISS-52 and BLISS-76 trials

Belimumab 10 mg/kg (%)

Belimumab 1 mg/kg (%)

Placebo (%)


SRI response rate at 52 weeks (BLISS-52)

58 (P = 0.0006)

51 (P = 0.0129)

44

SRI response rate at 52 weeks (BLISS-76)

43.2 (P = 0.017)

40.6 (P = 0.089)

33.5

SRI response rate at 76 weeks (BLISS-76)

38.5 (P = 0.13)

39.1 (P = 0.11)

32.4

Prednisone dose reduced ≥25%, to ≤7.5% mg/day during weeks 40 to 52 (BLISS-52)

19 (P = 0.0526)

21 (P = 0.025)

12

Prednisone dose reduced ≥25%, to ≤7.5% mg/day during weeks 40 to 52 (BLISS-76)

17.5 (P >0.05)

19.2 (P >0.05)

12.7


SRI, Systemic Lupus Erythematosus Responder Index.

Boneparth and Davidson Arthritis Research & Therapy 2012 14(Suppl 4):S2   doi:10.1186/ar3920